Cancer risk with tocilizumab/sarilumab, abatacept, and rituximab treatment in patients with rheumatoid arthritis : a Danish cohort study
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
OBJECTIVES: To investigate cancer risk in rheumatoid arthritis (RA) patients treated with tocilizumab/sarilumab, abatacept, or rituximab compared with those who received tumour necrosis factor inhibitors (TNFi) and compared with biological disease-modifying anti-rheumatic drugs (bDMARD) naïve RA patients.
METHODS: Nationwide registry-based cohort study of RA patients initiating treatment with tocilizumab/sarilumab, abatacept, rituximab, TNFi, and bDMARD-naive patients their second type of conventional synthetic DMARD (csDMARD). Patients were identified in DANBIO and followed for cancer from 2006-2020. Patients could contribute multiple treatments, with person years (PYRS), deaths, and cancers allocated to each treatment group in a 'latest type of treatment' manner. Inverse probability of treatment weighting and weighted cause-specific Cox models were used to calculate hazard ratios (HRs) for cancer in each tocilizumab/sarilumab, abatacept, and rituximab group compared with TNFI and bDMARD naïve groups, respectively.
RESULTS: In total, 21 982 treatment initiations, 96 475 PYRS, and 1423 cancers were identified. There were no statistically significant increased HRs for overall cancer in tocilizumab/sarilumab, abatacept, or rituximab treatment groups (HRs ranged from 0.7-1.1). More than five years of abatacept exposure showed a non-significantly increased HR compared with TNFi (HR 1.41, 95% confidence intervals CI 0.74-2.71). For hematological cancers, rituximab treatment showed non-significantly reduced HRs: vs TNFi (HR 0.09; 95%CI 0.00-2.06) and bDMARD-naïve (HR 0.13; 95%CI 0.00-1.89).
CONCLUSION: Treatment with tocilizumab/sarilumab, abatacept, or rituximab in RA patients was not associated with increased risks of cancer compared with TNFi-treated and with bDMARD-naïve RA patients in a real-world setting.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Rheumatology (Oxford, England) - (2024) vom: 07. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Westermann, Rasmus [VerfasserIn] |
---|
Links: |
---|
Themen: |
Abatacept |
---|
Anmerkungen: |
Date Revised 07.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1093/rheumatology/keae140 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369420470 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM369420470 | ||
003 | DE-627 | ||
005 | 20240308233055.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240308s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/rheumatology/keae140 |2 doi | |
028 | 5 | 2 | |a pubmed24n1320.xml |
035 | |a (DE-627)NLM369420470 | ||
035 | |a (NLM)38452297 | ||
035 | |a (PII)keae140 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Westermann, Rasmus |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cancer risk with tocilizumab/sarilumab, abatacept, and rituximab treatment in patients with rheumatoid arthritis |b a Danish cohort study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 07.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
520 | |a OBJECTIVES: To investigate cancer risk in rheumatoid arthritis (RA) patients treated with tocilizumab/sarilumab, abatacept, or rituximab compared with those who received tumour necrosis factor inhibitors (TNFi) and compared with biological disease-modifying anti-rheumatic drugs (bDMARD) naïve RA patients | ||
520 | |a METHODS: Nationwide registry-based cohort study of RA patients initiating treatment with tocilizumab/sarilumab, abatacept, rituximab, TNFi, and bDMARD-naive patients their second type of conventional synthetic DMARD (csDMARD). Patients were identified in DANBIO and followed for cancer from 2006-2020. Patients could contribute multiple treatments, with person years (PYRS), deaths, and cancers allocated to each treatment group in a 'latest type of treatment' manner. Inverse probability of treatment weighting and weighted cause-specific Cox models were used to calculate hazard ratios (HRs) for cancer in each tocilizumab/sarilumab, abatacept, and rituximab group compared with TNFI and bDMARD naïve groups, respectively | ||
520 | |a RESULTS: In total, 21 982 treatment initiations, 96 475 PYRS, and 1423 cancers were identified. There were no statistically significant increased HRs for overall cancer in tocilizumab/sarilumab, abatacept, or rituximab treatment groups (HRs ranged from 0.7-1.1). More than five years of abatacept exposure showed a non-significantly increased HR compared with TNFi (HR 1.41, 95% confidence intervals CI 0.74-2.71). For hematological cancers, rituximab treatment showed non-significantly reduced HRs: vs TNFi (HR 0.09; 95%CI 0.00-2.06) and bDMARD-naïve (HR 0.13; 95%CI 0.00-1.89) | ||
520 | |a CONCLUSION: Treatment with tocilizumab/sarilumab, abatacept, or rituximab in RA patients was not associated with increased risks of cancer compared with TNFi-treated and with bDMARD-naïve RA patients in a real-world setting | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Abatacept | |
650 | 4 | |a Biologics | |
650 | 4 | |a Cancer | |
650 | 4 | |a Real-world evidence | |
650 | 4 | |a Rheumatoid arthritis | |
650 | 4 | |a Rituximab | |
650 | 4 | |a Sarilumab | |
650 | 4 | |a Tocilizumab | |
700 | 1 | |a Cordtz, René Lindholm |e verfasserin |4 aut | |
700 | 1 | |a Duch, Kirsten |e verfasserin |4 aut | |
700 | 1 | |a Mellemkjaer, Lene |e verfasserin |4 aut | |
700 | 1 | |a Hetland, Merete Lund |e verfasserin |4 aut | |
700 | 1 | |a Magnussen, Bergur |e verfasserin |4 aut | |
700 | 1 | |a Dreyer, Lene |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g (2024) vom: 07. März |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:07 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keae140 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 07 |c 03 |